Add Formweb to your mobile device
| 2016 P&T Formulary Decisions | |
| August | Approval of 900.6520 Therapeutic Interchange: Topical Corticosteroids |
| June |
Mifepristone (Mifeprex) added to formulary with restriction to OB providers in Legacy Medical Group who have registered in REMS program. Sugammadex (Bridion) added to formulary with restriction to anesthesia providers for reversal of rocuronium or vecuronium. Tirofiban (Aggrastat) added to formulary to replace eptifibatide. Eptifibatide (Integrelin) removed from formulary. May be available for patients already started on eptifibatide. |
| May | Capsaicin 8% (Qutenza) added to formulary with restriction to Pain Clinic use only. |
| April |
Filgrastim (Neupogen) removed from formulary for adults. Remains formulary for pediatrics. tbo-filgrastim (Granix) added to formulary with therapeutic interchange from filgrastim. |
| March |
Netupitant/palonosetron (Akynzeo) not added to formulary. Aprepritant (Emend) added additional indications. Approved oral and suspension for chemotherapy induced nausea and vomiting only. Not reviewed for post-operative nausea and vomiting- non-formulary for this indication. Fosaprepitant added to formulary for oncology related nausea and vomiting. Palonosetron (Aloxin) added to formulary for oncology related nausea and vomiting. Pyridoxine/Doxylamine (Diclegis) not added to formulary. |
| January | Idarucizumb (Praxbind) added to formulary for reversal of Pradaxa only. |
|
P&T Minutes 2014 |
December 2014
Formulary: Melatonin approved for use
Formulary: Ramelteon (Rozerem) NOT added to formulary
Formulary: Sodium Fleet Enema REMOVED from formulary
August 2014
Formulary: Bupivacaine liposome (Exparel) usage expanded under restrictions
June 2014
Formulary: Change from moxifloxacin to levofloxacin
Other: Topical Corticosteroids Formulary Class Review. Therapeutic Interchange approved
DUE: Ertapenem usage evaluated
May 2014
Formulary: Tolvaptan
DUE: Daptomycin usage evaluated
April 2014
Formulary: Bupivacaine liposome (Exparel) approved for use with restrictions
Other: Nafcillin to oxacillin Therapeutic Interchange for shortages approved
January 2014
DUE: IV Acetaminophen usage evaluated
Other: Sublingual Nitroglycerin Therapeutic Interchange Approved
|
P&T Minutes 2013 |
November 2013
Formulary: Bupivacaine liposome (Exparel) – decision deferred
August 2013
Formulary: 4-factor PCC (Kcentra) approved for use
June 2013
DUE: Prothrombin Complex Concentrate (PCC) use evaluated
DUE: Dabigatran (Pradaxa) use evaluated
May 2013
Formulary: eculizumab (Soliris) approved for use with restrictions
Formulary: Icatibant (Firazyr) NOT added to formulary
April 2013
Formulary: Alemtuzumab (Campath) approved for use
March 2013
Formulary: Alvimopan (Entereg) approved for use
Formulary: Apixaban (Eliquis) approved for use
|
P&T Minutes 2012 |
September 2012
Formulary: Fibrinogen Concentrate approved for use with restrictions
August 2012
Formulary: Formulary Change for LMWH to enoxaparin
March 2012
Formulary: Ticagrelor (Brilinta) added to formulary
February 2012
Formulary: Liposomal Amphotericin Formulary Review. Change to Ambisome as the formulary agent
Formulary: IV Ibuprofen LGS trial results and approval for continued use
DUE: Methylnaltrexone use evaluated and dosing defaults changed
January 2012
Formulary: Fidaxomicin (Deficid) NOT added to formulary. Non-formulary use restricted to ID and GI practitioners.
Formulary: Ceftaroline (Teflaro) NOT added to formulary. Non-formulary use restricted to ID practitioners.